Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 17,531 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Agent Clear all
Completed No phase listed Observational Accepts healthy volunteers

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

NCT04755777
View directory record Official record
Conditions
Sepsis, Critical Illness
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 28, 2026, 2:07 PM EDT
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 28, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

NCT04679012
View directory record Official record
Conditions
Richter Syndrome, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab, Etoposide, Prednisone, Cyclophosphamide, Hydroxydaunomycin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

NCT02019667
View directory record Official record
Conditions
Metabolic Disease, Seizures
Interventions
SGS-742, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
4 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

NCT02644967
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IMO-2125, Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

NCT02425111
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
La Jolla, California • Hamden, Connecticut • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 28, 2026, 2:07 PM EDT
Terminated Phase 3 Interventional

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 28, 2026, 2:07 PM EDT
Recruiting Phase 2 Interventional

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Interventions
TORL-1-23, Pegfilgrastim (drug)
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

NCT00651612
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 28, 2026, 2:07 PM EDT
Withdrawn Phase 3 Interventional

Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy

NCT02717728
View directory record Official record
Conditions
Hip Surgery Corrective, Anesthesia; Functional
Interventions
Drug group Fascia iliaca nerve block, Control group sham nerve block
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 28, 2026, 2:07 PM EDT
Completed No phase listed Observational

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

NCT04002700
View directory record Official record
Conditions
Stroke
Interventions
Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,234,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Modified Stem Cells in Stable Ischemic Stroke

NCT01287936
View directory record Official record
Conditions
Chronic Ischemic Stroke
Interventions
SB623
Biological
Lead sponsor
SanBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Stanford, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 28, 2026, 2:07 PM EDT
Terminated Phase 2 Interventional Results available

Albumin for Intracerebral Hemorrhage Intervention

NCT00990509
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Albumin, Placebo, Brain MRI with and without contrast
Drug · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 28, 2026, 2:07 PM EDT
Terminated Phase 1 Interventional

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

NCT03300921
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Paricalcitol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

NCT01475721
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
11,751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
350
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 28, 2026, 2:07 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

NCT07861321
View directory record Official record
Conditions
Dental Caries
Interventions
Nano Silver Fluoride / NSF
Device
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
6 Years to 10 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 2:07 PM EDT
Active, not recruiting Phase 1 Interventional

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

NCT04337177
View directory record Official record
Conditions
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Interventions
VAL-413, Temozolomide
Drug
Lead sponsor
Valent Technologies, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

NCT00509301
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00569777
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
K-Lens (generic name not established) and Ketotifen, Placebo Lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Gardena, California • North Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 2:07 PM EDT
Terminated Phase 3 Interventional

Extended Management and Measurement of Autism

NCT00787111
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine (prozac)
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
5 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

Contrast Enhanced Ultrasound for Renal Obstruction

NCT05090800
View directory record Official record
Conditions
Kidney; Obstruction, Renal Obstruction
Interventions
Definity contrast during ultrasound
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 28, 2026, 2:07 PM EDT